phenylmethyl 2-[(2-bromophenyl)methyl]imidazole-4-carboxylate | 332882-94-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenylmethyl 2-[(2-bromophenyl)methyl]imidazole-4-carboxylate
• 英文别名: benzyl 2-[(2-bromophenyl)methyl]-1H-imidazole-5-carboxylate
• CAS: 332882-94-7
• 化学式: C₁₈H₁₅BrN₂O₂
• 分子量: 371.233
• InChiKey: KCNCBPCTFBUXAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenylmethyl 2-[(2-bromophenyl)methyl]imidazole-4-carboxylate 、 4-溴-2-丁烯酸甲酯 生成 methyl (2E)-4-{2-[(2-bromophenyl)methyl]-4-[benzyloxycarbonyl]imidazolyl}but-2-enoate
  参考文献：
  名称：

  Fused cycloheptane and fused azacycloheptane compounds and their methods of use

  摘要：

  该发明涵盖了新颖的化合物，对预防和治疗疾病有效，例如通过整合素受体介导的疾病，特别是通过整合素受体介导的疾病或症状，如αvβ3、αvβ5、αvβ6等。该发明涵盖了新颖的化合物，其药学上可接受的盐，药物组合物以及预防和治疗此类疾病和疾患的方法。该发明还涉及制备此类化合物的方法以及在此类方法中有用的中间体。

  公开号：

  US06514964B1

文献信息

• FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Amgen Inc.

  公开号：EP1216230A2

  公开（公告）日：2002-06-26
• US6514964B1
  申请人：——

  公开号：US6514964B1

  公开（公告）日：2003-02-04
• [EN] FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSES DE CYCLOHEPTANE FONDU ET D'AZACYCLOHEPTANE FONDU ET LEURS PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2001023357A2

  公开（公告）日：2001-04-05

  The invention comprises novel compounds of formula E-B-(Alk)p-Q-(Alk)q-A-G wherein G is a radical of formula (I), (II) or (III) that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as αvβ3, αvβ5, αvβ6 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
• Fused cycloheptane and fused azacycloheptane compounds and their methods of use
  申请人：Amgen Inc.

  公开号：US06514964B1

  公开（公告）日：2003-02-04

  The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as &agr;v&bgr;3, &agr;v&bgr;5, &agr;v&bgr;6 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  该发明涵盖了新颖的化合物，对预防和治疗疾病有效，例如通过整合素受体介导的疾病，特别是通过整合素受体介导的疾病或症状，如αvβ3、αvβ5、αvβ6等。该发明涵盖了新颖的化合物，其药学上可接受的盐，药物组合物以及预防和治疗此类疾病和疾患的方法。该发明还涉及制备此类化合物的方法以及在此类方法中有用的中间体。